ALBO News and Press, Albireo Pharma Inc.

Bylvay (odevixibat) granted Priority Review by U.S. FDA ASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patients Approval in second indication would more than double Bylvay market oppo...

NEW YORK, NY / ACCESSWIRE / February 9, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Trean Insurance Group, Inc. (NASDA...

NEW YORK, NY / ACCESSWIRE / February 8, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Oak Street Health, Inc. (NYSE:OSH)'s ...

Summary The backbone of the Albireo is Bylvay, a product in a platform already approved in one indication and expected to be approved in two significant larger indications. Ipsen recognizes the huge potential and is offering $42 plus a $10 CVR to acquire Albireo. The deal is expected to...

NEW YORK, NY / ACCESSWIRE / February 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Albireo Pharma, Inc. (NASDAQ:ALBO)...

Summary Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 mill...

NEW YORK, NY / ACCESSWIRE / February 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Albireo Pharma, Inc. (NASDAQ:ALBO) to Ipsen is fair to Albireo shareholders. Per the terms of the proposed transaction, Ipsen would acquire Albireo for $42.00 per sh...

NEW YORK, NY / ACCESSWIRE / January 26, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CinCor Pharma, Inc. (NASDAQ:CINC)'...

NEW YORK, NY / ACCESSWIRE / January 25, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CinCor Pharma, Inc. (NASDAQ:CINC)'...

NEW YORK, NY / ACCESSWIRE / January 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Concert Pharmaceuticals, Inc. (NASDAQ...